Carvedilol

Limits on what this shows

• Key negative/null findings: Felix et al. 2017 (rats) reported carvedilol exacerbated gentamicin-induced kidney mitochondrial alterations, the opposite direction from the cardioprotective pattern described above, in a specific renal/nephrotoxic-drug-interaction context (title and citation confirmed via a PubMed search listing; the full abstract could not be retrieved in this review). This is carried on record as an important boundary: the protective pattern documented elsewhere is not universal across organs or co-administered drugs.
• At-risk subgroups: None established in humans. The Felix 2017 rat finding suggests only a theoretical caution specific to concurrent nephrotoxic aminoglycoside therapy, not a general mitochondrial-burden risk from carvedilol alone.
• Dose/duration: Every protective and inhibitory effect above was observed only in isolated-mitochondria or cell-culture systems at experimenter-selected concentrations; Pereira 2011 explicitly separates "therapeutic" from "high" in vitro concentrations, and no in vitro concentration in these studies has been mapped onto a recommended human dose. No dose or duration recommendation follows from any of this.

Regulatory status

Not addressed anywhere in the label.

Population evidence

Entirely Tier B (in vitro/animal); no Tier A human cohort study of carvedilol and mitochondrial burden was located. A body of work from one research group (Moreno, Oliveira, Santos and colleagues, Coimbra) spanning 1998-2010 in isolated rat heart mitochondria found carvedilol reduced lipid peroxidation of mitochondrial membranes (Moreno 1998), inhibited the mitochondrial permeability transition pore when triggered by oxidative stress (calcium plus phosphate, or calcium plus t-butylhydroperoxide) but not when triggered by carboxyatractyloside, attributing the effect to antioxidant rather than direct pore-binding chemistry (Cardiovasc Toxicol 2004), and protected respiratory control ratios and P/O ratios against hypoxanthine/xanthine-oxidase-generated oxidative damage (Cardiovasc Toxicol 2001). Separately, carvedilol protected against doxorubicin-induced mitochondrial cardiomyopathy in rats (Santos 2002) and in human iPSC-derived cardiomyocytes by phenocopying PGC-1alpha overexpression (Uche 2023), and against cisplatin-induced renal mitochondrial toxicity (Rodrigues 2010); Yao et al. 2016 reported carvedilol promoted mitochondrial biogenesis via the PGC-1/TFAM pathway in human umbilical vein endothelial cells (title, authors, journal and DOI confirmed; the full abstract could not be retrieved in repeated attempts during this review, see Sources).

Mechanism

A dual, concentration-dependent pharmacology, described in a carvedilol-specific mitochondrial-toxicology review (Pereira et al. 2011, Curr Pharm Des): at concentrations "higher than therapeutic levels," carvedilol acts as a weak protonophore, lowering mitochondrial membrane potential, and inhibits respiratory-chain Complex I; the same review states these cardioprotective, antioxidant-driven effects are "unrelated with its hemodynamic effects," making this a genuine direct mitochondrial pharmacology rather than simply a downstream consequence of beta-blockade. At concentrations relevant to therapeutic dosing, the protective direction dominates in every model examined here.

Counter-evidence held on record

Sgobbo et al. 2007 titled their H9C2-cell study "Carvedilol inhibits mitochondrial complex I and induces resistance to H2O2-mediated oxidative insult," naming both a direct inhibitory action and a protective one in the same paper; only the title itself could be confirmed in this review after repeated access attempts (see Sources), so no magnitude or concentration detail from it is asserted here. Felix 2017 is the clearest adverse-direction counter-finding on record and is retained specifically so this entry does not read as uniformly reassuring. Present as "carvedilol has direct, concentration-dependent effects on mitochondria, mostly protective at therapeutic relevance, with an isolated adverse-direction finding in a kidney/gentamicin-co-administration animal model" — never as an established, uniform mitochondrial-protective or mitochondrial-toxic claim for carvedilol in people. No dose recommendation follows.

Limits on what this shows

• Key negative/null findings: Fahlbusch et al. 2004, a double-blind randomized crossover in 17 healthy men, found no statistically significant change in systemic oxidative-stress markers after 6 days of carvedilol versus metoprolol or placebo, despite an effect in cultured endothelial cells in vitro; the myocardial-tissue and post-MI effects above have not been shown to generalize to short-term dosing in healthy volunteers.
• At-risk subgroups: None; no subgroup was shown to have oxidative stress worsened by carvedilol. Patients with the most oxidative stress at baseline (failing myocardium, acute MI) showed the largest measured reductions.
• Dose/duration: Nakamura 2002 measured effects after a mean of about 9.4 months of individualized carvedilol therapy; Kastratovic 2007 measured effects within the first 168 hours of combined streptokinase-carvedilol therapy for acute MI; Fahlbusch 2004 used carvedilol 25 mg twice daily for 6 days in healthy volunteers. These figures describe what was studied, not a recommended dose or duration.

Regulatory status

Not addressed in the DailyMed label; no oxidative-stress biomarker monitoring is required or referenced anywhere in Clinical Pharmacology or Drug Interactions.

Population evidence

Nakamura et al. 2002 (Circulation) examined myocardial tissue from 23 patients with dilated cardiomyopathy against 13 non-failing controls, finding lipid-peroxide/oxidative-damage markers significantly elevated in failing myocardium; after carvedilol treatment (mean about 9.4 months), these markers fell by about 40% alongside improved cardiac function. Kastratovic et al. 2007 followed acute MI patients given streptokinase alone, streptokinase plus metoprolol, or streptokinase plus carvedilol, and found erythrocyte copper-zinc superoxide dismutase (CuZnSOD) activity rose at 6, 24, and 168 hours in the carvedilol arm (versus only at 24 hours with metoprolol), concluding carvedilol acted through both beta-blockade and direct antioxidant chemistry. Budni et al. 2012/2013 (already the evidentiary basis of the Vitamin E/C entry above) separately found reduced protein-carbonyl and TBARS oxidative-damage markers over 6 to 12 months of carvedilol in chronic Chagas cardiomyopathy; those studies are referenced here as supporting context, not re-counted as new grading weight (see Overlap map).

Mechanism

Carvedilol's carbazole moiety and its metabolites scavenge reactive oxygen species and inhibit lipid peroxidation directly, independent of beta- or alpha-1-receptor blockade. This is distinct from, and does not depend on, the unconfirmed CoQ10-enzyme-inhibition hypothesis carried in the Coenzyme Q10 entry above.

Counter-evidence held on record

This entry exists specifically to prevent carvedilol's well-documented antioxidant pharmacology from being filed as if it were evidence the drug depletes a nutrient or damages tissue oxidatively; the measured direction in every carvedilol-specific human study located is a reduction in oxidative-damage markers, not an increase. Fahlbusch 2004 is carried on record as the boundary condition: healthy volunteers, short exposure, no systemic effect detected. Present as "carvedilol has its own antioxidant, free-radical-scavenging chemistry, distinct from beta-blockade" — never as "carvedilol depletes antioxidants" or "carvedilol causes oxidative stress." This is not a basis for any antioxidant-supplement recommendation.

Limits on what this shows

• Key negative/null findings: No study measured serum copper, ceruloplasmin, or tissue copper in carvedilol-treated patients, so there is no positive or null carvedilol-specific copper-status result; the CuZnSOD activity increase is the only carvedilol-specific human enzyme-level finding available, and it runs in the direction of increased enzyme function, not depletion.
• At-risk subgroups: None established.
• Dose/duration: Kastratovic 2007 measured activity within 168 hours of starting combined streptokinase-carvedilol therapy for acute MI at individualized post-MI dosing; no copper-specific dose or monitoring figure exists to report, and none is recommended here.

Regulatory status

Not addressed in the label. No copper interaction or monitoring language appears anywhere in Drug Interactions or Clinical Pharmacology.

Population evidence

Kastratovic et al. 2007 measured erythrocyte CuZnSOD, catalase, glutathione peroxidase, and glutathione reductase activity in acute MI patients receiving streptokinase alone, streptokinase plus metoprolol, or streptokinase plus carvedilol; CuZnSOD activity rose at 6, 24, and 168 hours with carvedilol (versus only at 24 hours with metoprolol). This is a Tier A, carvedilol-specific human finding, but it measures the activity of a copper-requiring enzyme, not copper level or copper status itself; a rise in enzyme activity does not by itself establish a change in body copper stores. Zoroddu et al. 2003 characterized a copper(II) "superdimer" complex formed by carvedilol in vitro by crystallography and NMR (title, journal and DOI confirmed; full abstract not retrieved in this review). Yue et al. 1992 reported carvedilol prevented copper-catalyzed oxidation of LDL by macrophages in vitro (citation confirmed via a PubMed search listing only; the full abstract was not independently retrieved in this review).

Mechanism

Carvedilol's catechol/carbazole structure can coordinate copper ions directly (Zoroddu 2003), which in vitro blocks copper's catalytic role in generating reactive oxygen species during LDL oxidation (Yue 1992); this is a redox/chelation-adjacent mechanism, not a nutrient-transport, absorption, or excretion effect, and there is no evidence it lowers whole-body copper.

Counter-evidence held on record

No carvedilol-specific study has measured copper status directly, so this entry cannot rule out a subtle chelation-driven effect on copper availability; it is graded on the chemistry and enzyme-activity evidence that exists, not on an assumption of safety. The in vitro binding chemistry (Zoroddu 2003) and the LDL-oxidation protection (Yue 1992) could not be independently verified beyond their titles and citations in this review; that access limitation is disclosed rather than treated as confirmation. Present as "carvedilol interacts with copper chemically and appears to increase activity of a copper-dependent antioxidant enzyme in one post-MI cohort; whether this reflects, causes, or has no relationship to a change in body copper has not been tested" — never as "carvedilol depletes copper." No dose or supplementation recommendation follows.

Limits on what this shows

• Key negative/null findings: No study measured serum iron, ferritin, or transferrin saturation in carvedilol-treated patients. Human double-blind randomized trials of carvedilol in transfusion-dependent beta-thalassemia major (an iron-overload disease) measured cardiac function outcomes (left ventricular ejection fraction, diastolic function), not iron parameters, so they cannot be used as carvedilol-specific iron-status evidence; they are noted here only as confounding-by-indication context, since carvedilol is used in these patients for cardioprotection against iron-driven cardiomyopathy, a disease-management use, not evidence the drug itself changes iron status.
• At-risk subgroups: None established for a depletion effect. If anything, the in vitro literature suggests the direction of theoretical interest is protective in iron-overload states, not depleting.
• Dose/duration: All chelation/protection findings above are in vitro or in rats at experimenter-selected concentrations and doses not mapped to human dosing; no iron-related dose or monitoring recommendation follows from any of this.

Regulatory status

Not addressed in the label. No iron interaction is listed in Drug Interactions.

Population evidence

Entirely Tier B; no Tier A human iron-status study was located. Oettl et al. 2001 (Biochem Pharmacol), an in vitro chemistry study, found carvedilol chelates ferric ion with a binding constant of about 10^5 L/mol and concluded carvedilol "acts as both a metal chelator and a radical scavenger in vitro," noting that at carvedilol's low physiological plasma concentration, radical scavenging alone may not fully explain its antioxidative effect, implicating iron chelation as a contributing mechanism. Chan et al. 2014 (Acta Haematol), using ferric-chloride-exposed human umbilical vein endothelial cells, found iron induced microparticle generation, apoptosis, and reactive oxygen species in a dose-dependent manner, and that carvedilol, but not propranolol, mitigated these effects, concluding carvedilol's protection "may have therapeutic potential in patients with iron overload." Singh, Chander and Chopra 2003 (Toxicology) reported carvedilol and trimetazidine attenuated ferric-nitrilotriacetate-induced oxidative renal injury in rats (title, journal, and DOI confirmed; full abstract not retrieved in this review).

Mechanism

Direct ferric-ion chelation (binding constant about 10^5 L/mol) plus radical scavenging, both reducing iron's capacity to catalyze oxidative damage; this is chemically similar to, but mechanistically distinct from, carvedilol's copper-binding chemistry described in the independent Copper entry above, and neither has been shown to reduce whole-body or circulating iron.

Counter-evidence held on record

No human iron-status study exists for carvedilol in either direction, so this entry rests on chemistry and cell/animal protection data only, not on a confirmed absence of any human effect. The thalassemia cardioprotection trials are retained on record specifically to prevent a reader from mistaking "carvedilol is used in iron-overloaded patients" for "carvedilol affects iron levels." Present as "carvedilol binds iron and protects cells from iron-driven oxidative damage in laboratory models; no human study has measured whether this changes iron status" — never as "carvedilol depletes iron" or as an approved clinical iron-chelation effect. No dose or supplementation recommendation follows.

Limits on what this shows

• Key negative/null findings: The Wu 2024 taxonomic changes were mixed in direction: Akkermansia, generally considered a beneficial commensal genus, decreased, while Desulfovibrio, a sulfate-reducing genus sometimes associated with gut inflammation, increased; but the same study reported improved, not worsened, pain and mood outcomes in the animals, so this mixed signal did not translate to a measured harm in that model. No human carvedilol microbiome study, positive or null, was located.
• At-risk subgroups: None established in humans. The Wu 2024 model is specific to diabetic peripheral neuropathy, a disease state that independently alters gut microbiota; the finding cannot be separated from that disease background.
• Dose/duration: Wu 2024 used an animal-model dose and duration not mapped to human dosing; no dose or monitoring recommendation follows.

Regulatory status

Not addressed in the label.

Population evidence

Wu et al. 2024 (Biochem Biophys Res Commun), streptozotocin-induced diabetic mice with neuropathic pain and depressive behavior, found carvedilol treatment increased Prevotella, Ruminococcus, Helicobacter, and Desulfovibrio and decreased Akkermansia and Allobaculum, alongside improved mechanical hyperalgesia and depression-like behavior; the authors framed this as a beneficial gut-brain-axis effect. This is Tier B: carvedilol-specific, but in an animal disease model, not human status data. Separately, a 2024 narrative review of cardiovascular drugs and the gut/oral microbiome (Antibiotics/MDPI) states beta-blockers as a class "tend to decrease the overall microbial diversity," naming metoprolol, atenolol, propranolol, and bisoprolol specifically as the studied drugs; carvedilol was not among the drugs named in that review, making this Tier C class extrapolation for carvedilol, not carvedilol-specific evidence.

Mechanism

Not established for carvedilol specifically. The class-level hypothesis (reduced microbial diversity from beta-adrenergic blockade, or direct antibacterial activity as shown for propranolol against E. coli in the same review) has not been tested against carvedilol's distinct alpha-1-blocking and antioxidant chemistry.

Counter-evidence held on record

The only carvedilol-specific evidence is one diabetic-mouse study with a mixed-direction taxonomic signal and a net beneficial behavioral readout, confounded by the diabetic disease model itself; the class-level diversity-reduction evidence used to support plausibility did not include carvedilol among the drugs actually studied, so it is Tier C extrapolation only, per this dossier's cohort test. Present as "gut microbiota changes have been observed with carvedilol in one diabetic-mouse study, and with other beta-blockers as a class in humans, but no human carvedilol-specific microbiome study exists" — never as an established carvedilol gut-health risk or benefit. No dose, probiotic, or supplement recommendation follows.

Limits on what this shows

• Key negative/null findings: A separate isolated-mitochondria study (Oliveira, Cardiovasc Toxicol 2001) found carvedilol protected, rather than reduced, state III respiration and P/O ratios (a direct index of ATP produced per oxygen consumed) in mitochondria challenged with hypoxanthine/xanthine-oxidase-generated oxidative stress, the opposite direction from an ATP-impairing effect, at the same kind of in vitro exposure. No human study found reduced ATP production, phosphocreatine depletion, or any bioenergetic deficit attributable to carvedilol.
• At-risk subgroups: None demonstrated. Heart failure itself is independently associated with impaired myocardial energetics (reduced phosphocreatine/ATP ratio) before any drug is started; this is disease background, not a carvedilol effect, per this dossier's confounding-by-indication rule.
• Dose/duration: Wallhaus 2001 measured effects at whatever individualized carvedilol dose and titration each of the 9 patients had reached in routine heart-failure management, not a fixed study dose; the isolated-mitochondria studies used concentrations not mapped to a human dose. No dose or duration recommendation follows from either.

Regulatory status

Not addressed in the label; no ATP, phosphocreatine, or bioenergetic marker is referenced anywhere in Drug Interactions or Clinical Pharmacology.

Population evidence

Wallhaus et al. 2001 (Circulation), PET imaging in 9 patients with congestive heart failure, found carvedilol treatment produced a 57% decrease in myocardial free-fatty-acid use with no significant change in glucose use, alongside left ventricular ejection fraction improving from 26±2% to 37±4%; the authors framed this as improved myocardial energy efficiency, a shift toward the more oxygen-efficient glucose-oxidation pathway. No Tier A study measured ATP concentration, ATP synthesis rate, or phosphocreatine/ATP ratio directly in carvedilol-treated humans.

Mechanism

Two distinct, non-competing mechanisms appear in the literature. First, the Wallhaus finding reflects carvedilol's established heart-failure mechanism (reduced afterload and heart rate driving reverse remodeling and a substrate-utilization shift); this is the drug's known clinical action, not a novel ATP-production effect, and is recorded here as background rather than counted as independent evidence (see Overlap map and the confounding-by-indication caution). Second, isolated rat heart mitochondria studies (Oliveira 2000) and the Pereira 2011 review describe carvedilol as a weak protonophore/uncoupler and a Complex I inhibitor at higher in vitro concentrations, which would be expected to reduce ATP yield per unit of substrate if it occurred at physiological exposure; the same review states these effects occur only above therapeutic concentration.

Counter-evidence held on record

The Wallhaus 2001 finding is retained here only as background because it is the sole human bioenergetic measurement located for carvedilol, but it cannot be cleanly separated from the drug's known heart-failure mechanism of action, so it is not counted as independent evidence that carvedilol itself alters ATP production outside that therapeutic reverse-remodeling context. The in vitro uncoupling/Complex-I-inhibition literature is the more direct evidence of a drug-specific bioenergetic action, and it runs in a concentration-dependent, not uniformly harmful, direction. Never state that carvedilol depletes or impairs ATP production in people; the only human data point runs the opposite direction and is itself confounded by heart-failure treatment. No dose recommendation follows from any of this.

Limits on what this shows

• Key negative/null findings: Not applicable; there is no study to report a null result from.
• At-risk subgroups: None can be stated; there is no evidence base to define one.
• Dose/duration: Not applicable. No dose, monitoring, or supplementation point can be derived from an evidence gap.

Regulatory status

Not addressed in the label; no hemoglobin, hematocrit, or oxygen-saturation monitoring requirement is listed.

Population evidence

Searches located several carvedilol studies of exercise oxygen uptake (VO2) and heart-rate kinetics in heart-failure patients (Karsten et al. 2012; Guazzi et al. 1998, 1999), but every one of these measures the drug's known therapeutic hemodynamic and chronotropic effect (reduced heart rate, changed loading conditions, and, in the Guazzi studies, pulmonary gas-transfer limitation from the underlying heart failure itself), not a distinguishable effect on oxygen delivery or cellular oxygen utilization capacity. Per this dossier's rule against filing a drug's own known clinical mechanism as a separate physiological finding, these are excluded rather than counted here. A targeted search for carvedilol and hemoglobin, erythropoietin, red-cell mass, or tissue/cytochrome-oxidase-level oxygen utilization returned no carvedilol-specific study of any tier.

Mechanism

None identified, Tier A through C, for carvedilol specifically or for beta-blockers as a class, distinct from hemodynamic output.

Counter-evidence held on record

This gap was checked deliberately: exercise-oxygen-uptake and hemodynamic studies exist for carvedilol in abundance, but every one located folds back into the drug's known heart-failure therapeutic mechanism rather than isolating a distinct oxygen-delivery or oxygen-utilization effect, and no consumer nutrient-depletion source claims a carvedilol effect on oxygen delivery to rebut as white. Both conditions for UNGRADED are met: no Tier B/C mechanistic support, and no circulating claim to rebut. Present as "no evidence currently links carvedilol to a change in oxygen delivery or utilization independent of its therapeutic cardiac effect" — an open question, not a clean bill of health and not a depletion claim. No dose or monitoring recommendation follows from an evidence gap.